Cecilia Bai focuses her practice on capital markets and corporate transactions, including initial public offerings, private equity financings, mergers and acquisitions and general corporate representation.
ImmuneOnco Biopharmaceuticals – HK$319 Million IPO
September 5, 2023
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million initial public offering.
